 |
Entrada Therapeutics
Last updated: September 01, 2025
CEO - Dipal Doshi
USA | Funding: $301.6M (+)
Website: https://www.entradatx.com/
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases such as Duchenne muscular dystrophy (DMD).
Website: https://www.entradatx.com/
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases such as Duchenne muscular dystrophy (DMD).
